Kulbacka-Ortiz, Katarzyna
Triest, Filip J. J.
Franssen, Frits M. E.
Wouters, Emiel F. M.
Studnicka, Michael
Vollmer, William M.
Lamprecht, Bernd
Burney, Peter G. J.
Amaral, Andre F. S.
Vanfleteren, Lowie E. G. W. http://orcid.org/0000-0002-4387-4096
Funding for this research was provided by:
Aventis
AstraZeneca
Boehringer Ingelheim
Chiesi Farmaceutici
GlaxoSmithKline
Merck
Novartis Pharmaceuticals Corporation
Pfizer UK
Schering-Plough
Sepracor
University of Kentucky
Hjärt-Lungfonden (20200150)
Familjen Kamprads Stiftelse (20190024)
Swedish government and country council ALF grant (ALFGBG-824371)
Wellcome Trust (085790/Z/08/Z)
University of Gothenburg
Article History
Received: 9 March 2021
Accepted: 24 January 2022
First Online: 17 February 2022
Declarations
:
: Approval was obtained from each local ethics committee, and written informed consent was obtained from each participant. Indian Institute of Environmental Medicine, Mumbai, India, approval IIEM/IEC/005/2004-05; Chest Research Foundation Independent Ethics Committee, KEM Hospital Research Centre, Pune, India, approval 19/6/2008, KEMHRC/VSP/Dir.Off/EC/539 and KEMHRC ID No. 0931; Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India, approval SIMS-1-31-IEC/2010-2557 (research protocol 6/2010); Philippine National Ethics Committee, Philippines approval 7/3/2008; University of Cape Town, Cape Town, South Africa, approval 152/2003; Kyrgyz National Centre of Cardiology and Internal Medicine, approval 01-7/49 of 6/2/2013; Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria, approval ERC/2011/01/04; Etablissement Hospitalier Specialise Universitaire de Medecine Physique et Readaptation de Seraidi, approval 13/S/M/2012; Comite National d’Ethique de la Recherche pour la Sante Humaine, approval 2013/11/373/L/CNERSH/SP; University Hospital Farhat Hached, Sousse, Tunisia, approval 24/4/2010; University of Tartu, Tartu, Estonia, approval 118/53; National Bioethics Committee, Reykjavik, Iceland, approval 04-080; Regional Committee for Medical and Health Research Ethics of Western Norway (REK Vest), Bergen, Norway, approval 098.05; Regional Ethical Review Board in Uppsala, Uppsala, Sweden, approval 2006/146; Bioethics Committee of the Jagiellonian University Medical School, Krakow, Poland, approval KBET/36/B/2005; Charing Cross Hospital, London, UK, approval 06/Q0411/97; Hannover Medical School, Hannover, Germany, approval 3804/2004; University of Kentucky, Lexington, Kentucky, approval 04-0714-F3R; Hospital Pulido Valente, Lisbon, Portugal, approval CE/25/07 (Estudo 21/07); Academic hospital of Maastricht (azM) and Maastricht University (UM), Maastricht, The Netherlands, approval MEC-062-084; Ethics Committee for the State of Salzburg, Salzburg, Austria, approval 556/10a; University of Sydney, Sydney, Australia, approval 12-2005/1/8641; University of British Columbia/Providence Health Care, approval P05-0061; Adana Valiligi Provincial Health Directorate, Adana, Turkey, approval 03-15-442; Guangzhou Institute of Respiratory Disease, Guangzhou, China, approval 2003-01; Philippine National Ethics Committee, Philippines, approval 9/8/2005; Ethics Review Committee of the Faculty of Medicine of the University of Kelaniya, Sri Lanka (FWA00013225), approval P5/01/2011; National Bioethics Committee, Ministry of Health, Republic of Albania, approval 18 (10/6/2011); National Guard-Health Affairs, King Abdulaziz Medical City, Institutional Review Board, approval IRBC/038/11 (5/3/2011); Joint Penang Independent Ethics Committee, approval JPEC 12-12-0202 (11/12/2012).
: Not applicable.
: FMEF reports grants and personal fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Novartis, non-financial support from TEVA, outside the submitted work. KKO, FJJT, BL, PGJB, EFMW, WMV, AFSA, MS, LEGWV report no competing interests.